Aug 7 (Reuters) - ANI Pharmaceuticals Inc ::ANI PHARMACEUTICALS REPORTS SECOND QUARTER RESULTS.Q2 ADJUSTED NON-GAAP EARNINGS PER SHARE $1.44.Q2 GAAP EARNINGS PER SHARE $0.53.Q2 REVENUE ROSE 15 PERCENT TO $54.4 MILLION.SEES FY 2019 SALES UP 9 TO 12 PERCENT.SEES FY 2019 REVENUE $220 MILLION TO $226 MILLION.ANI HAS UPDATED ITS FULL YEAR GUIDANCE FOR NET REVENUES DUE TO COMPETITIVE LANDSCAPE OF METHYLPHENIDATE ER MARKET.AS OF JUNE 30, 2019 CASH AND CASH EQUIVALENTS $40.5 MILLION.SEES 2019 ADJUSTED NON-GAAP DILUTED EARNINGS PER SHARE $5.57 TO $6.21.
Full Article
June 18 (Reuters) - ANI Pharmaceuticals Inc ::ANI PHARMACEUTICALS EXPANDS GENERIC PIPELINE WITH ACQUISITION OF SEVEN DEVELOPMENT STAGE DRUG PRODUCTS FROM COEPTIS PHARMACEUTICALS, INC..ANI PHARMACEUTICALS EXPANDS GENERIC PIPELINE WITH ACQUISITION OF SEVEN DEVELOPMENT STAGE DRUG PRODUCTS FROM COEPTIS PHARMACEUTICALS, INC..ANI PHARMACEUTICALS INC - DEAL FOR FOR $2.3 MILLION DOLLARS.ANI PHARMACEUTICALS INC - DEAL INCLUDES UP TO $12.0 MILLION IN ADDITIONAL DEVELOPMENT AND COMMERCIAL MILESTONES.
Full Article
May 9 (Reuters) - ANI Pharmaceuticals Inc ::ANI PHARMACEUTICALS REPORTS FIRST QUARTER 2019 RESULTS AND REAFFIRMS GUIDANCE.Q1 ADJUSTED NON-GAAP EARNINGS PER SHARE $1.30.Q1 GAAP EARNINGS PER SHARE $0.04.Q1 REVENUE $52.9 MILLION VERSUS REFINITIV IBES ESTIMATE OF $50.6 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $1.05 -- REFINITIV IBES DATA.REAFFIRMED ITS 2019 FINANCIAL GUIDANCE.
Full Article
Dec 27 (Reuters) - ANI Pharmaceuticals Inc ::ANI PHARMACEUTICALS - ON DEC 27,CO, UNITS ENTERED INTO AMENDED & RESTATED 5-YEAR SENIOR SECURED CREDIT AMENDING CREDIT FACILITY DATED DEC 29, 2017.ANI PHARMACEUTICALS - AMENDED CREDIT AGREEMENT ADDS DELAYED DRAW TERM LOAN FACILITY IN AN AMOUNT UP TO $118.0 MILLION.ANI PHARMACEUTICALS - AMENDED CREDIT AGREEMENT INCREASES BORROWING CAPACITY UNDER REVOLVING LINE OF CREDIT BY $25.0 MILLION TO $75.0 MILLION - SEC FILING.ANI PHARMACEUTICALS - AMENDED CREDIT AGREEMENT ALSO EXTENDS MATURITY, INCLUDING OUTSTANDING $72.2 MILLION INITIAL TERM LOAN, TO DEC 27, 2023.ANI PHARMACEUTICALS SAYS TOTAL SIZE OF AMENDED CREDIT AGREEMENT IS $265.2 MILLION FOLLOWING AMENDMENT AND RESTATEMENT - SEC FILING.
Full Article
Nov 6 (Reuters) - ANI Pharmaceuticals Inc ::ANI PHARMACEUTICALS REPORTS THIRD QUARTER AND YEAR-TO-DATE 2018 RESULTS AND REAFFIRMS GUIDANCE.Q3 ADJUSTED NON-GAAP EARNINGS PER SHARE $1.29.Q3 GAAP EARNINGS PER SHARE $0.42.Q3 REVENUE $50.7 MILLION VERSUS I/B/E/S VIEW $51 MILLION.Q3 EARNINGS PER SHARE VIEW $1.17 -- THOMSON REUTERS I/B/E/S.SAYS REAFFIRMED ITS 2018 FINANCIAL GUIDANCE.
Full Article
April 4 (Reuters) - ANI Pharmaceuticals Inc - Deal For $2.6 Mln And A Limited Single ::ANI ACQUIRES 23 ANDAS FROM IDT AUSTRALIA, LTD..DIGIT ROYALTY FOR ONE PRODUCT.
Full Article
Feb 27 (Reuters) - ANI Pharmaceuticals Inc ::ANI PHARMACEUTICALS REPORTS RECORD FULL YEAR RESULTS, REPORTS FOURTH QUARTER 2017 RESULTS, AND PROVIDES 2018 GUIDANCE.Q4 ADJUSTED NON-GAAP EARNINGS PER SHARE $1.08.Q4 REVENUE ROSE 24 PERCENT TO $47.3 MILLION.QTRLY GAAP NET LOSS INCLUDES IMPACT OF $13.4 MILLION CHARGE DUE TO TAX CUTS AND JOBS ACT.QTRLY DILUTED GAAP LOSS PER SHARE OF $0.83.SEES 2018 NET REVENUES OF $212 MILLION TO $228 MILLION.SEES 2018 ADJUSTED NON-GAAP DILUTED EARNINGS PER SHARE OF $5.43 TO $6.08.PLANS TO INVEST APPROXIMATELY $7 MILLION IN CAPITAL PROJECTS DURING 2018.
Full Article
Dec 29 (Reuters) - Ani Pharmaceuticals Inc ::ANI PHARMACEUTICALS ACQUIRES FOUR NDAS FROM ASTRAZENECA FOR $46.5 MILLION.ANI PHARMACEUTICALS INC - ACQUISITIONS WERE FUNDED THROUGH A COMBINATION OF CASH AND DEBT.ANI PHARMACEUTICALS SAYS ADDITION OF ASSETS WILL BE MATERIAL TO REVENUE AND EBITDA IN 2018.
Full Article
Nov 2 (Reuters) - ANI Pharmaceuticals Inc :ANI Pharmaceuticals reports record third quarter and year-to-date 2017 results and narrows full year guidance.Q3 adjusted Non-GAAP earnings per share $1.11.Q3 GAAP earnings per share $0.40.Q3 revenue $48.2 million versus I/B/E/S view $48.1 million.Q3 earnings per share view $0.99 -- Thomson Reuters I/B/E/S.ANI Pharmaceuticals Inc sees for full year 2017 net revenues $181 million to $183 million.ANI Pharmaceuticals Inc sees for full year 2017 adjusted Non-GAAP diluted earnings per share $3.83 to $4.00.Q3 earnings per share view $0.99, revenue view $48.1 million -- Thomson Reuters I/B/E/S.FY2017 earnings per share view $3.84, revenue view $182.1 million -- Thomson Reuters I/B/E/S.ANI Pharmaceuticals Inc - ANI intends to request a meeting with fda in Q4 of 2017 to present its regulatory filing plan.
Full Article
Earnings vs. 
Estimates